HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Clinical Trial: Which is Better Induction Therapy, RVD or CRD? Study Open for Newly Diagnosed Myeloma Patients
Posted: Oct 13, 2016
Clinical Trial: Which is Better Induction Therapy, RVD or CRD? Study Open for Newly Diagnosed Myeloma Patients image

Which up-front therapy combination is best for newly diagnosed multiple myeloma patients? This study is comparing two proteasome inhibitors which are combined with lenalidomide (an iMiD) and dexamethasone (a steroid.) The class of proteasome inhibitors are are critical staple for myeloma therapy, but is one better than another? We are hopeful that this clinical trial can give insight into which proteasome inhibitor is best for which type of patient, age, pre-existing conditions and myeloma genetics. This trial is open in many locations on the East coast including local cancer centers, and will include over 700 newly diagnosed multiple myeloma patients. To learn more about this study or to join, click here: RVD or CRD Clinical Trial for Newly Diagnosed Patients  

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube